News Center

News Center

Home page

Blog Center

News Center

Viwit Pharmaceutical's Phenylephrine Hydrochloride Injection Officially Receives Official Approval by China NMPA

Viwit Pharmaceuticals’ Brimonidine tartrate and Timolol maleate eye drops receive Official Approval by China NMPA

Viwit's Nitroglycerin Sublingual Tablets Approved by FDA

Viwit Pharmaceuticals API Site Successfully Passed FDA cGMP On-site Audit with "No Action Indicated"

Viwit Pharmaceutical Co. Ltd. announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable contrast agents in the US.

Viwit Pharmaceutical’s Lifitegrast API has completed registrations in both China and the US!

Meeting Viwit Pharmaceuticals at CPHI Barcelona

Author：

Release Time：

2023-09-18

Viwit Pharmaceuticals will be participating in CPHI Barcelona 2023 in Oct. 24^th~26^th, 2023 at Fira Barcelona Gran Via, Spain. Welcome to visit our booth 7D30 or contact us to learn more about our full portfolio of products, services, and solutions. We look forward to seeing you soon!

Viwit’s Business scope:

► APIs, Boranes, Intermediates and Finished products;

► CMO/CDMO for key starting materials, advanced intermediates, APIs, and FDFs.

Previous

Viwit Pharmaceuticals’BFS Technology

SST Corporation and Viwit Pharmaceuticals Establish Strategic Collaboration

Next

VIWIT

Technical Support:China Enterprise Cross-border | SEO Tags

【Business License】

Search